[
  {
    "ts": "2026-01-30T01:10:30+00:00",
    "headline": "Is Regeneron (REGN) Offering Value After Recent Share Price Softness?",
    "summary": "If you are wondering whether Regeneron Pharmaceuticals is attractively priced right now, it helps to separate the headlines from what the numbers are actually saying about value. The share price recently closed at US$749.44, with returns of 10.3% over 1 year, 0.3% over 3 years, and 51.1% over 5 years. However, the year-to-date move of a 3.5% decline and shorter-term returns of a 0.8% decline over 7 days and a 3.2% decline over 30 days show that the ride has not been perfectly smooth. Recent...",
    "url": "https://finance.yahoo.com/news/regeneron-regn-offering-value-recent-011030093.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7f180661-209d-3803-a9f7-58b63241cef2",
      "content": {
        "id": "7f180661-209d-3803-a9f7-58b63241cef2",
        "contentType": "STORY",
        "title": "Is Regeneron (REGN) Offering Value After Recent Share Price Softness?",
        "description": "",
        "summary": "If you are wondering whether Regeneron Pharmaceuticals is attractively priced right now, it helps to separate the headlines from what the numbers are actually saying about value. The share price recently closed at US$749.44, with returns of 10.3% over 1 year, 0.3% over 3 years, and 51.1% over 5 years. However, the year-to-date move of a 3.5% decline and shorter-term returns of a 0.8% decline over 7 days and a 3.2% decline over 30 days show that the ride has not been perfectly smooth. Recent...",
        "pubDate": "2026-01-30T01:10:30Z",
        "displayTime": "2026-01-30T01:10:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w30LARiR1Z35GusfaFi.2g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3eDp_RSETU8kXm3usDK_gQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-regn-offering-value-recent-011030093.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-regn-offering-value-recent-011030093.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-30T09:19:59+00:00",
    "headline": "Oil Earnings, Inflation Data, Likely Fed Chair Decision: Still to Come This Week",
    "summary": "More earnings are due, as well as a reading on monthly supplier inflation. Here is what to watch: Today   Earnings: American Express, Chevron, Exxon Mobil, Regeneron, Verizon   Economic data: Producer-price index for December   Federal Reserve news: President Trump has said he plans to unveil his pick to lead the central bank this morning.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-30-2026/card/oil-earnings-inflation-data-possible-fed-chair-decision-still-to-come-this-week-4JZmobIBGKqBZ3jozBR8?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "112c499f-1156-35ee-8107-bd5a9444068c",
      "content": {
        "id": "112c499f-1156-35ee-8107-bd5a9444068c",
        "contentType": "STORY",
        "title": "Oil Earnings, Inflation Data, Likely Fed Chair Decision: Still to Come This Week",
        "description": "",
        "summary": "More earnings are due, as well as a reading on monthly supplier inflation. Here is what to watch: Today   Earnings: American Express, Chevron, Exxon Mobil, Regeneron, Verizon   Economic data: Producer-price index for December   Federal Reserve news: President Trump has said he plans to unveil his pick to lead the central bank this morning.",
        "pubDate": "2026-01-30T09:19:59Z",
        "displayTime": "2026-01-30T09:19:59Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/112c499f-1156-35ee-8107-bd5a9444068c/oil-earnings-inflation-data-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8",
          "originalWidth": 1200,
          "originalHeight": 630,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AC.ajdS9OghfMNW3mzlvpg--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 1200,
              "height": 630,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J5JxVR9DmLuomtxdXBS7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7b2c285183be07ca3c4e8242b25a59a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-30-2026/card/oil-earnings-inflation-data-possible-fed-chair-decision-still-to-come-this-week-4JZmobIBGKqBZ3jozBR8?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VZ"
            },
            {
              "symbol": "AXP"
            },
            {
              "symbol": "CVX"
            },
            {
              "symbol": "XOM"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-30T11:30:00+00:00",
    "headline": "Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results",
    "summary": "Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024Fourth quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 34% to $4.9 billion versus fourth quarter 2024; full year 2025 Dupixent global net sales increased 26% to $17.8 billion versus 2024Fourth quarter 2025 EYLEA HD® U.S. net sales increased 66% to $506 million and total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.",
    "url": "https://finance.yahoo.com/news/regeneron-reports-fourth-quarter-full-113000099.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "eeb98b01-ee6f-3f71-a49e-c51c4b52e6c3",
      "content": {
        "id": "eeb98b01-ee6f-3f71-a49e-c51c4b52e6c3",
        "contentType": "STORY",
        "title": "Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results",
        "description": "",
        "summary": "Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024Fourth quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 34% to $4.9 billion versus fourth quarter 2024; full year 2025 Dupixent global net sales increased 26% to $17.8 billion versus 2024Fourth quarter 2025 EYLEA HD® U.S. net sales increased 66% to $506 million and total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.",
        "pubDate": "2026-01-30T11:30:00Z",
        "displayTime": "2026-01-30T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
          "originalWidth": 800,
          "originalHeight": 126,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ohIVokMiKClSVTQVwyB2lw--~B/aD0xMjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 800,
              "height": 126,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YuYzNeQcIK6rRYN1HdT6UA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-reports-fourth-quarter-full-113000099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-reports-fourth-quarter-full-113000099.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-30T12:56:15+00:00",
    "headline": "Sanofi touts strong new launch sales amid looming Dupixent patent expiry",
    "summary": "The company’s sales grew 9.9% YoY – driven by a diverse range of portfolio classics and new launches.",
    "url": "https://www.pharmaceutical-technology.com/news/sanofi-fy2025-sales-results/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "0f6a201b-751d-3bcf-80d7-0d99934eaffb",
      "content": {
        "id": "0f6a201b-751d-3bcf-80d7-0d99934eaffb",
        "contentType": "STORY",
        "title": "Sanofi touts strong new launch sales amid looming Dupixent patent expiry",
        "description": "",
        "summary": "The company’s sales grew 9.9% YoY – driven by a diverse range of portfolio classics and new launches.",
        "pubDate": "2026-01-30T12:56:15Z",
        "displayTime": "2026-01-30T12:56:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/c16e6ff343f752d745d66ededfc02392",
          "originalWidth": 1000,
          "originalHeight": 562,
          "caption": "Sanofi achieved 9.9% sales growth YoY in FY2025. Image credit: Grand Warszawski via ShutterStock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NioagWY6ow7lrdTKuLZD_g--~B/aD01NjI7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/c16e6ff343f752d745d66ededfc02392.cf.webp",
              "width": 1000,
              "height": 562,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K61WEjtHZX4YTja.jAVl9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/c16e6ff343f752d745d66ededfc02392.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/sanofi-fy2025-sales-results/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sanofi-touts-strong-launch-sales-125615800.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-30T12:40:59+00:00",
    "headline": "Regeneron beats quarterly profit estimates on Dupixent strength",
    "summary": "Jan 30 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, helped by strong demand for its eczema treatment, Dupixent.",
    "url": "https://finance.yahoo.com/news/regeneron-beats-quarterly-profit-estimates-124059778.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "c4e8310e-a9af-3be6-916c-aa8c8071e6bc",
      "content": {
        "id": "c4e8310e-a9af-3be6-916c-aa8c8071e6bc",
        "contentType": "STORY",
        "title": "Regeneron beats quarterly profit estimates on Dupixent strength",
        "description": "",
        "summary": "Jan 30 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, helped by strong demand for its eczema treatment, Dupixent.",
        "pubDate": "2026-01-30T12:40:59Z",
        "displayTime": "2026-01-30T12:40:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/4142c63313665abf52811aeffcaaf05d",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UypCAll_d9N5DenmBBg98g--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/4142c63313665abf52811aeffcaaf05d.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L1GyC12h_ZCWHqRksDsHjw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/4142c63313665abf52811aeffcaaf05d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-beats-quarterly-profit-estimates-124059778.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-beats-quarterly-profit-estimates-124059778.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-30T11:47:15+00:00",
    "headline": "Regeneron: Q4 Earnings Snapshot",
    "summary": "The Tarrytown, New York-based company said it had net income of $7.86 per share. Earnings, adjusted for stock option expense and non-recurring costs, came to $11.44 per share. The results beat Wall Street expectations.",
    "url": "https://finance.yahoo.com/news/regeneron-q4-earnings-snapshot-114715079.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "b9aabcbc-ca6a-34bc-9e9a-2200b5840ac7",
      "content": {
        "id": "b9aabcbc-ca6a-34bc-9e9a-2200b5840ac7",
        "contentType": "STORY",
        "title": "Regeneron: Q4 Earnings Snapshot",
        "description": "",
        "summary": "The Tarrytown, New York-based company said it had net income of $7.86 per share. Earnings, adjusted for stock option expense and non-recurring costs, came to $11.44 per share. The results beat Wall Street expectations.",
        "pubDate": "2026-01-30T11:47:15Z",
        "displayTime": "2026-01-30T11:47:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-q4-earnings-snapshot-114715079.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-q4-earnings-snapshot-114715079.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-30T11:40:37+00:00",
    "headline": "Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025",
    "summary": "Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 2.5% year on year to $3.88 billion. Its non-GAAP profit of $11.44 per share was 6.9% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/regeneron-nasdaq-regn-posts-better-114037111.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "0094c474-d966-3179-ac8a-7f9a7d1fe626",
      "content": {
        "id": "0094c474-d966-3179-ac8a-7f9a7d1fe626",
        "contentType": "STORY",
        "title": "Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025",
        "description": "",
        "summary": "Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 2.5% year on year to $3.88 billion. Its non-GAAP profit of $11.44 per share was 6.9% above analysts’ consensus estimates.",
        "pubDate": "2026-01-30T11:40:37Z",
        "displayTime": "2026-01-30T11:40:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "REGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E5YeVaDzgHlFxvDwMx9gpg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6HLp77Q1Eazwpb8zaGf6Xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-nasdaq-regn-posts-better-114037111.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-nasdaq-regn-posts-better-114037111.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-30T13:47:27+00:00",
    "headline": "Regeneron Handily Beat Fourth-Quarter Forecasts — Here's Why Shares Fell",
    "summary": "Regeneron stock took a hit early Friday on its higher-than-expected 2026 cost outlook following a fourth-quarter beat.",
    "url": "https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q4-2025/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "97f9f029-e325-3c5d-b335-2eced905f825",
      "content": {
        "id": "97f9f029-e325-3c5d-b335-2eced905f825",
        "contentType": "STORY",
        "title": "Regeneron Handily Beat Fourth-Quarter Forecasts — Here's Why Shares Fell",
        "description": "",
        "summary": "Regeneron stock took a hit early Friday on its higher-than-expected 2026 cost outlook following a fourth-quarter beat.",
        "pubDate": "2026-01-30T13:47:27Z",
        "displayTime": "2026-01-30T13:47:27Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/97f9f029-e325-3c5d-b335-2eced905f825/regeneron-handily-beat.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/9740f3ecddfb49b1d626a4e35f12ec63",
          "originalWidth": 1000,
          "originalHeight": 565,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JZQsKpFA3tEMyUbLghxmQw--~B/aD01NjU7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/9740f3ecddfb49b1d626a4e35f12ec63.cf.webp",
              "width": 1000,
              "height": 565,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LUwpAwXYCgBRIXZv9WmSaA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/9740f3ecddfb49b1d626a4e35f12ec63.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q4-2025/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-30T12:40:01+00:00",
    "headline": "Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates",
    "summary": "Regeneron (REGN) delivered earnings and revenue surprises of +8.32% and +1.77%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finance.yahoo.com/news/regeneron-regn-q4-earnings-revenues-124001396.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "cb95d5fb-0d8c-3a45-9402-03eeb26b71db",
      "content": {
        "id": "cb95d5fb-0d8c-3a45-9402-03eeb26b71db",
        "contentType": "STORY",
        "title": "Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates",
        "description": "",
        "summary": "Regeneron (REGN) delivered earnings and revenue surprises of +8.32% and +1.77%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?",
        "pubDate": "2026-01-30T12:40:01Z",
        "displayTime": "2026-01-30T12:40:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ynQsYX5ACHYPVbgtuT.Zxg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fz_9jpPkz.3eCTXvWlvRfQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-regn-q4-earnings-revenues-124001396.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-regn-q4-earnings-revenues-124001396.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-30T15:22:08+00:00",
    "headline": "Regeneron Yo-Yos, But Hints That It Could Be Ready To Flex Its Dealmaking Muscles",
    "summary": "Regeneron stock yo-yoed after Friday's open on the potential for business development deals following a solid fourth-quarter report.",
    "url": "https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q4-2025/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "97f9f029-e325-3c5d-b335-2eced905f825",
      "content": {
        "id": "97f9f029-e325-3c5d-b335-2eced905f825",
        "contentType": "STORY",
        "title": "Regeneron Yo-Yos, But Hints That It Could Be Ready To Flex Its Dealmaking Muscles",
        "description": "",
        "summary": "Regeneron stock yo-yoed after Friday's open on the potential for business development deals following a solid fourth-quarter report.",
        "pubDate": "2026-01-30T15:22:08Z",
        "displayTime": "2026-01-30T15:22:08Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/97f9f029-e325-3c5d-b335-2eced905f825/regeneron-yo-yos-but-hints.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/9740f3ecddfb49b1d626a4e35f12ec63",
          "originalWidth": 1000,
          "originalHeight": 565,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JZQsKpFA3tEMyUbLghxmQw--~B/aD01NjU7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/9740f3ecddfb49b1d626a4e35f12ec63.cf.webp",
              "width": 1000,
              "height": 565,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LUwpAwXYCgBRIXZv9WmSaA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/9740f3ecddfb49b1d626a4e35f12ec63.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/regeneron-stock-regeneron-pharmaceuticals-earnings-q4-2025/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-30T16:28:28+00:00",
    "headline": "Regeneron Pharmaceuticals Q4 Earnings Call Highlights",
    "summary": "Regeneron Pharmaceuticals (NASDAQ:REGN) closed out 2025 with what executives described as another “solid quarter of commercial execution,” highlighted by continued growth in Dupixent, Libtayo, and EYLEA HD, as well as a slate of upcoming regulatory and clinical catalysts. On the company’s fourth-qua",
    "url": "https://www.marketbeat.com/instant-alerts/regeneron-pharmaceuticals-q4-earnings-call-highlights-2026-01-30/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "43beca4e-0b0f-3bcb-aa00-4c9d9a5ecd90",
      "content": {
        "id": "43beca4e-0b0f-3bcb-aa00-4c9d9a5ecd90",
        "contentType": "STORY",
        "title": "Regeneron Pharmaceuticals Q4 Earnings Call Highlights",
        "description": "",
        "summary": "Regeneron Pharmaceuticals (NASDAQ:REGN) closed out 2025 with what executives described as another “solid quarter of commercial execution,” highlighted by continued growth in Dupixent, Libtayo, and EYLEA HD, as well as a slate of upcoming regulatory and clinical catalysts. On the company’s fourth-qua",
        "pubDate": "2026-01-30T16:28:28Z",
        "displayTime": "2026-01-30T16:28:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/b220205eea669f37dd99617bab6b355e",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Regeneron Pharmaceuticals logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FnJXt0gTXLzpr8K3cT4aKw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/b220205eea669f37dd99617bab6b355e.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6RjMjYL.oqR9bYpuWyHr4A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/b220205eea669f37dd99617bab6b355e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/regeneron-pharmaceuticals-q4-earnings-call-highlights-2026-01-30/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/regeneron-pharmaceuticals-q4-earnings-call-162828407.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-30T16:14:15+00:00",
    "headline": "Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season",
    "summary": "Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings results soon.",
    "url": "https://www.investors.com/research/ibd-industry-themes/dow-jones-amgenamgn-stock-biotech-stocks/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "55ede24c-7c02-3726-bce3-64125bdd2bfc",
      "content": {
        "id": "55ede24c-7c02-3726-bce3-64125bdd2bfc",
        "contentType": "STORY",
        "title": "Dow Jones Leader Amgen Leads These Biotech Stocks Heading Into Q4 Earnings Season",
        "description": "",
        "summary": "Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings results soon.",
        "pubDate": "2026-01-30T16:14:15Z",
        "displayTime": "2026-01-30T16:14:15Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/55ede24c-7c02-3726-bce3-64125bdd2bfc/dow-jones-leader-amgen-leads.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/a51e06a42dad42daf42ae2446bba7b62",
          "originalWidth": 1000,
          "originalHeight": 565,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YwEF8EnysyWP3eNxS9n0tQ--~B/aD01NjU7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/a51e06a42dad42daf42ae2446bba7b62.cf.webp",
              "width": 1000,
              "height": 565,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D8bJ88Zz2RoCmhhZhBk8ug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/a51e06a42dad42daf42ae2446bba7b62.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/research/ibd-industry-themes/dow-jones-amgenamgn-stock-biotech-stocks/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "ARGNF"
            },
            {
              "symbol": "ARGX"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-30T14:12:22+00:00",
    "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Geopolitical Tensions Loom While Investors Still Await Fed Rate Cut",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.4% and the actively tr",
    "url": "https://finance.yahoo.com/news/exchange-traded-funds-equity-futures-141222648.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "cf37c547-8138-32e7-95a4-77dc81caea9e",
      "content": {
        "id": "cf37c547-8138-32e7-95a4-77dc81caea9e",
        "contentType": "STORY",
        "title": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Geopolitical Tensions Loom While Investors Still Await Fed Rate Cut",
        "description": "",
        "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.4% and the actively tr",
        "pubDate": "2026-01-30T14:12:22Z",
        "displayTime": "2026-01-30T14:12:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/exchange-traded-funds-equity-futures-141222648.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/exchange-traded-funds-equity-futures-141222648.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "QQQ"
            },
            {
              "symbol": "XLP"
            },
            {
              "symbol": "IYW"
            },
            {
              "symbol": "XSD"
            },
            {
              "symbol": "VIS"
            },
            {
              "symbol": "XLF"
            },
            {
              "symbol": "FAS"
            },
            {
              "symbol": "IWM"
            },
            {
              "symbol": "PMR"
            },
            {
              "symbol": "VHT"
            },
            {
              "symbol": "EXI"
            },
            {
              "symbol": "USO"
            },
            {
              "symbol": "IYE"
            },
            {
              "symbol": "EETH"
            },
            {
              "symbol": "SNDR"
            },
            {
              "symbol": "XOM"
            },
            {
              "symbol": "FLG"
            },
            {
              "symbol": "XLK"
            },
            {
              "symbol": "UNG"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "IYJ"
            },
            {
              "symbol": "XLE"
            },
            {
              "symbol": "IYH"
            },
            {
              "symbol": "DECK"
            },
            {
              "symbol": "IBB"
            },
            {
              "symbol": "BITO"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "SOXX"
            },
            {
              "symbol": "IGV"
            },
            {
              "symbol": "FAZ"
            },
            {
              "symbol": "XRT"
            },
            {
              "symbol": "RTH"
            },
            {
              "symbol": "XLY"
            },
            {
              "symbol": "IPK"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "VDC"
            },
            {
              "symbol": "IYK"
            },
            {
              "symbol": "SLV"
            },
            {
              "symbol": "XLI"
            },
            {
              "symbol": "EEM"
            },
            {
              "symbol": "SPOT"
            },
            {
              "symbol": "BETH"
            },
            {
              "symbol": "GLD"
            },
            {
              "symbol": "IGM"
            },
            {
              "symbol": "IVV"
            },
            {
              "symbol": "SPY"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]